- Home
- PMVP vs VTGN Comparison
PMVP vs VTGN Comparison
Compare PMVP & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | VTGN |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 21.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PMVP | VTGN |
|---|---|---|
| Price | $1.56 | $0.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $5.00 | $0.90 |
| AVG Volume (30 Days) | ★ 815.0K | 736.7K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $0.43 |
| 52 Week High | $1.88 | $5.14 |
Technical Indicators
Market Signals| Indicator | PMVP | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 44.36 |
| Support Level | $1.32 | $0.50 |
| Resistance Level | $1.56 | $0.65 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 60.71 | 54.55 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.